NeuroDiscovery closes IPO
Friday, 12 August, 2005
Perth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) has closed its $1.5 million IPO and completed its acquisition of UK-based NeuroSolutions.
NeuroDiscovery offered 7.5 million shares at an issue price of AUD$0.20 each to raise the $1.5 million. NeuroSolutions - which has a mature pipeline of programs for the treatment of pain - is expected to commence Phase I and II clinical trials in the next 18 months.
NeuroDiscovery expects to list on the ASX on Monday 15 August.
Modifications in the placenta linked to psychiatric disorders
Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...
ADHD may be linked with an increased risk of dementia
An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...
Placebos appear to reduce PMS symptoms
Women affected by premenstrual syndrome (PMS) appear to experience less intense and debilitating...
